
Feature|Videos|January 2, 2025
Site Selection for CAR T-cell Trials
How the right site can set up for a successful clinical trial for CAR T-cell therapy.
Advertisement
Episodes in this series

Site selection for CAR T-cell clinical trials is a complex process that requires the right expertise, capability, and facility. Infrastructure is another major factor to consider as patients will often stay at the site after dosing to be safely monitored. The panelists walk Pharmaceutical Executive through the criteria they look for when selecting a site for their clinical trials.
Advertisement
Related to this article

Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.

Innogen grants Arcera exclusive rights to its long-acting GLP-1 receptor agonist across Africa, Eastern Europe, Latin America and the Middle East.

With rising healthcare costs, practices are embracing flexible payment models and upfront pricing transparency to keep care accessible.

Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.

Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.

DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks
2
Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo
3
FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis
4
How Pharma Organizations Can Scale AI Agents and Stay Audit-Ready
5










